TORONTO, ONTARIO--(Marketwire - February 24, 2009) - Attention: Business/Financial Editors
The Medipattern Corporation (TSX VENTURE: MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, and NAVIX Diagnostix, Inc. the leading provider of vascular ultrasound outsourcing solutions in the northeastern U.S. are pleased to announce that NAVIX will collect data for the development of Medipattern's vascular imaging tool, VasculariQ™. The American Heart Association cites an estimated 80,700,000 American adults (one in three) have one or more types of cardiovascular disease (CVD) and the statistics echo throughout the global population. Medipattern recently announced an agreement with GE Healthcare to create a set of image quantification tools to help physicians visualize plaque and other conditions that can block the vascular system. Vascular diseases are estimated to be among the highest causes of lifestyle impairment, including stroke, amputation and heart attack.
"When I saw the proof of concept results from CADenza, I knew that Medipattern's technology approach for VasculariQ had the potential to change the way that we plan intervention for vascular diseases. The technology may also have the ability to predict the potential development of adverse events. Currently, treatment options used to address vascular disease are lifestyle modifications, like smoking cessation, diet and exercise, medication; minimally invasive procedures including angioplasty and stenting; and open surgery. Patient care is most improved when physicians are able to determine the best treatment option; however choosing the best method may be problematic. With VasculariQ, Medipattern's tool set can assist physicians to make a more informed decision about treatment options for the millions of people diagnosed with vascular diseases," stated Bob Kane, Senior Vice President of Clinical Services and Business Development of NAVIX. "Under the agreement Medipattern will receive real-time ultrasound images and supporting information for known vascular diseases."
"Under the agreement with GE Healthcare, GE and Medipattern have been working on a proof of concept for the vascular quantification tool that we shared with Bob Kane and his colleagues at NAVIX. GE Healthcare's Vascular Ultrasound team is committed to developing new technology to image and analyze vascular disease, increasing diagnostic confidence and speeding patient treatment," commented Jeff Collins, CEO of The Medipattern Corporation. "Medipattern's CADenza platform has already proven to be valuable in breast ultrasound imaging. This project will leverage our technology to address vascular morphology. The data we have gathered under HIPAA and FDA compliant methods is key to the success of the project and clinical studies. Partnering with industry expert NAVIX, enables Medipattern to accelerate product development. Medipattern used the same type of approach in developing our award winning B-CAD® product. Navix has multiple lab locations from Maine to Washington DC, collecting this volume of data will enable us to rapidly develop and test VasculariQ. We are very honoured to be able to work with NAVIX."
2009 Upcoming Events:
- NCBC (National Consortium of Breast Centers), March 14-16, 2009 in Las Vegas NV sponsored by GE and SonoCine
- AIUM (American Institute of Ultrasound in Medicine), April 2-5, 2009 in NYC, NY sponsored by GE
- BIC (Breast Imaging Conference), September 4-5, 2009 in Nashville, TN sponsored by GE
About NAVIX Diagnostix
NAVIX Diagnostix, Inc. is a privately held company providing cardiovascular management solutions for hospitals and medical practices, combining a passion for patient care with operational excellence. Navix' Vascular Early Detection Initiative (VEDI™), is a routine, risk-focused screening program aimed at early detection for individuals most at risk for peripheral arterial disease (PAD). Navix was responsible for deploying one of the first Intersocietal Commission for the Accreditation of Vascular Labs (ICAVL) accredited screening programs in the U.S. www.navixdiagnostics.com.
About The Medipattern Corporation:
Medipattern® is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: www.medipattern.com.
B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.